Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this research, RNA expression analysis of scalp biopsies from lichen planopilaris patients revealed changes in specific genes after treatments with hydroxychloroquine, narrow band UVB, or low level laser light therapy, suggesting potential biomarkers and implicating M2 macrophages in the disease's immunopathogenesis.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This case report by the researchers observed a complete remission of lichen planopilaris in a 58-year-old woman after treatment with the JAK-1 inhibitor abrocitinib, although they noted that concurrent topical therapy might have contributed to this outcome.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.